These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23652277)

  • 1. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
    Twardowski PW; Beumer JH; Chen CS; Kraft AS; Chatta GS; Mitsuhashi M; Ye W; Christner SM; Lilly MB
    Anticancer Drugs; 2013 Aug; 24(7):743-53. PubMed ID: 23652277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
    Yu EY; Wilding G; Posadas E; Gross M; Culine S; Massard C; Morris MJ; Hudes G; Calabrò F; Cheng S; Trudel GC; Paliwal P; Sternberg CN
    Clin Cancer Res; 2009 Dec; 15(23):7421-8. PubMed ID: 19920114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
    Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
    Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
    Araujo JC; Mathew P; Armstrong AJ; Braud EL; Posadas E; Lonberg M; Gallick GE; Trudel GC; Paliwal P; Agrawal S; Logothetis CJ
    Cancer; 2012 Jan; 118(1):63-71. PubMed ID: 21976132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
    Spreafico A; Chi KN; Sridhar SS; Smith DC; Carducci MA; Kavsak P; Wong TS; Wang L; Ivy SP; Mukherjee SD; Kollmannsberger CK; Sukhai MA; Takebe N; Kamel-Reid S; Siu LL; Hotte SJ
    Invest New Drugs; 2014 Oct; 32(5):1005-16. PubMed ID: 24788563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
    Passildas-Jahanmohan J; Eymard JC; Pouget M; Kwiatkowski F; Van Praagh I; Savareux L; Atger M; Durando X; Abrial C; Richard D; Ginzac Couvé A; Thivat E; Monange B; Chollet P; Mahammedi H
    Cancer Med; 2021 Apr; 10(7):2332-2340. PubMed ID: 33666378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
    Lara PN; Longmate J; Evans CP; Quinn DI; Twardowski P; Chatta G; Posadas E; Stadler W; Gandara DR
    Anticancer Drugs; 2009 Mar; 20(3):179-84. PubMed ID: 19396016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).
    Dorff TB; Quinn DI; Pinski JK; Goldkorn A; Sadeghi S; Tsao-Wei D; Groshen S; Kuhn P; Gross ME
    Clin Genitourin Cancer; 2019 Aug; 17(4):241-247.e1. PubMed ID: 31227432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
    Yu EY; Massard C; Gross ME; Carducci MA; Culine S; Hudes G; Posadas EM; Sternberg CN; Wilding G; Trudel GC; Paliwal P; Fizazi K
    Urology; 2011 May; 77(5):1166-71. PubMed ID: 21539969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
    Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 trial of dasatinib in advanced melanoma.
    Kluger HM; Dudek AZ; McCann C; Ritacco J; Southard N; Jilaveanu LB; Molinaro A; Sznol M
    Cancer; 2011 May; 117(10):2202-8. PubMed ID: 21523734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
    Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.
    Herold CI; Chadaram V; Peterson BL; Marcom PK; Hopkins J; Kimmick GG; Favaro J; Hamilton E; Welch RA; Bacus S; Blackwell KL
    Clin Cancer Res; 2011 Sep; 17(18):6061-70. PubMed ID: 21810917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
    Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
    Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
    Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
    Brooks HD; Glisson BS; Bekele BN; Johnson FM; Ginsberg LE; El-Naggar A; Culotta KS; Takebe N; Wright J; Tran HT; Papadimitrakopoulou VA
    Cancer; 2011 May; 117(10):2112-9. PubMed ID: 21523723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
    Miller AA; Pang H; Hodgson L; Ramnath N; Otterson GA; Kelley MJ; Kratzke RA; Vokes EE;
    J Thorac Oncol; 2010 Mar; 5(3):380-4. PubMed ID: 20087228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.